Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

508 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network.
Lorscheider J, Signori A, Subramaniam S, Benkert P, Vukusic S, Trojano M, Hillert J, Glaser A, Hyde R, Spelman T, Magyari M, Elberling F, Pontieri L, Koch-Henriksen N, Sørensen PS, Gerlach O, Prat A, Girard M, Eichau S, Grammond P, Horakova D, Ramo-Tello C, Roos I, Buzzard K, Lechner Scott J, Sánchez-Menoyo JL, Alroughani R, Prévost J, Kuhle J, Gray O, Mathey G, Michel L, Ciron J, De Sèze J, Maillart E, Ruet A, Labauge P, Zephir H, Kwiatkowski A, van der Walt A, Kalincik T, Butzkueven H; Italian MS Register; Observatoire Français de la Sclérose en Plaques (OFSEP); MSBase Study Group; Swedish MS Registry; Big MS Data Network. Lorscheider J, et al. J Neurol Neurosurg Psychiatry. 2024 Dec 6:jnnp-2024-334700. doi: 10.1136/jnnp-2024-334700. Online ahead of print. J Neurol Neurosurg Psychiatry. 2024. PMID: 39643429 Free article.
Association between education level and access to disease-modifying treatment in patients with multiple sclerosis in France.
Lefort M, Dejardin O, Berger E, Camdessanché JP, Ciron J, Clavelou P, De Sèze J, Debouverie M, Heinzlef O, Labauge P, Laplaud DA, Michel L, Lebrun-Frénay C, Moreau T, Pelletier J, Ruet A, Thouvenot E, Vukusic S, Zephir H, Defer G, Leray E. Lefort M, et al. Among authors: moreau t. Mult Scler. 2025 Jan;31(1):69-80. doi: 10.1177/13524585241289276. Epub 2024 Dec 1. Mult Scler. 2025. PMID: 39618051
Association between education level and disability progression in patients with multiple sclerosis in France.
Lefort M, Dejardin O, Berger E, Camdessanché JP, Ciron J, Clavelou P, De Sèze J, Debouverie M, Heinzlef O, Labauge P, Laplaud DA, Le Page E, Lebrun-Frénay C, Moreau T, Pelletier J, Ruet A, Thouvenot E, Vukusic S, Zephir H, Defer G, Leray E. Lefort M, et al. Among authors: moreau t. Mult Scler. 2025 Jan;31(1):59-68. doi: 10.1177/13524585241289274. Epub 2024 Nov 30. Mult Scler. 2025. PMID: 39614776
TEC-ADHERE: Real-World Persistence and Adherence on Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis in the French OroSEP Patient-Support Program.
Labauge P, Créange A, Moreau T, Nouvet-Gire J, Pedespan B, Heinzlef O, Texier N, Gros M, Marti C, Ruiz M, Martinez M, Castelnovo G. Labauge P, et al. Among authors: moreau t. Neurol Ther. 2024 Nov 11. doi: 10.1007/s40120-024-00674-x. Online ahead of print. Neurol Ther. 2024. PMID: 39527163
Anti-CD20 Therapies in Drug-Naive Patients With Primary Progressive Multiple Sclerosis: A Multicenter Real-Life Study.
Hay M, Rollot F, Casey R, Kerbrat A, Edan G, Mathey G, Labauge P, De Sèze J, Vukusic S, Laplaud DA, Papeix C, Moreau T, Thouvenot E, Defer G, Lebrun-Frénay C, Ciron J, Berger E, Stankoff B, Clavelou P, Maillart E, Heinzlef O, Zéphir H, Ruet A, Casez O, Moulin S, Al-Khedr A, Bourre B, Pelletier J, Magy L, Neau JP, Camdessanché JP, Doghri I, Wahab A, Tchikviladzé M, Labeyrie C, Hankiewicz K, Le Page E, Michel L; as the OFSEP Investigators. Hay M, et al. Among authors: moreau t. Neurology. 2024 Oct 22;103(8):e209886. doi: 10.1212/WNL.0000000000209886. Epub 2024 Sep 25. Neurology. 2024. PMID: 39321406
Frequent detection of IFN-gamma -producing memory effector and effector T cells in patients with progressive multifocal leukoencephalopathy.
de Goër de Herve MG, Dekeyser M, Hendel-Chavez H, Maillart E, Labeyrie C, Adams D, Moreau T, Lubetzki C, Papeix C, Stankoff B, Gasnault J, Taoufik Y. de Goër de Herve MG, et al. Among authors: moreau t. Front Immunol. 2024 Jul 17;15:1416074. doi: 10.3389/fimmu.2024.1416074. eCollection 2024. Front Immunol. 2024. PMID: 39086476 Free PMC article.
Early Maintenance Treatment Initiation and Relapse Risk Mitigation After a First Event of MOGAD in Adults: The MOGADOR2 Study.
Deschamps R, Guillaume J, Ciron J, Audoin B, Ruet A, Maillart E, Pique J, Benyahya L, Laplaud DA, Michel L, Collongues N, Cohen M, Ayrignac X, Thouvenot E, Zephir H, Bourre B, Froment Tilikete C, Moreau T, Cantagrel P, Kerschen P, Cabasson S, Maubeuge N, Hankiewicz K, Nifle C, Berger E, Megherbi H, Magy L, Klapczynski F, Sarov Riviere M, Giannesini C, Hamelin L, Giroux M, Branger P, Maurousset A, Mathey G, Moulin M, Mélé N, Papeix C, Marignier R; as the NOMADMUS study group. Deschamps R, et al. Among authors: moreau t. Neurology. 2024 Aug 13;103(3):e209624. doi: 10.1212/WNL.0000000000209624. Epub 2024 Jul 11. Neurology. 2024. PMID: 38991174
Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple Sclerosis.
Gavoille A, Rollot F, Casey R, Kerbrat A, Le Page E, Bigaut K, Mathey G, Michel L, Ciron J, Ruet A, Maillart E, Labauge P, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Berger E, Stankoff B, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Al-Khedr A, Casez O, Bourre B, Cabre P, Wahab A, Magy L, Camdessanché JP, Doghri I, Moulin S, Ben-Nasr H, Labeyrie C, Hankiewicz K, Neau JP, Pottier C, Nifle C, Manchon E, Lapergue B, Wiertlewski S, De Sèze J, Vukusic S, Laplaud DA; OFSEP Investigators. Gavoille A, et al. Among authors: moreau t. JAMA Neurol. 2024 Aug 1;81(8):814-823. doi: 10.1001/jamaneurol.2024.1961. JAMA Neurol. 2024. PMID: 38949816
508 results